PDCD1 and melanoma: Current studies have utilized microarray, SEREX cDNA library, immunofluorescence, and immunoassay technologies for screening of IMAE associated autoantibodies, such as thyroiditis, hypophysitis, rash, colitis, arthritis, myocarditis, myalgia, and endocrine disorders in response to singular/combination treatments of CTLA4, PD-1 and PD-L1 in melanoma, advanced/metastatic solid tumors, renal cell carcinoma, non-small cell lung, prostate, and bladder cancers (68–73).